Table 1 Clinical characteristics of study participants
Characteristics | All patients (n = 40) | No DVT after enrollment (n = 35) | DVT after enrollment (n = 5) |
|---|---|---|---|
Age at study entry (years), median (minimum – maximum) | 49 (20–71) | 49 (21–71) | 42 (20–59) |
Sex, n (%) | |||
 Male | 22 (55%) | 20 (57.2%) | 2 (40%) |
 Female | 18 (45%) | 15 (42.8%) | 3 (60%) |
Blood group, n (%) | |||
 O blood group | 8 (20%) | 8 (22.8%) | 0 (0%) |
 Non-O blood group (A, B, AB) | 32 (80%) | 27 (77.1%) | 5 (100%) |
Body mass index (kg/m2) | 19.4 (15.2–22.6) | 19.4 (16.5–22.6) | 19.7 (15.2–20.2) |
 Underweight | 11 (27.5%) | 9 (25.7%) | 2 (40%) |
 Normoweight | 29 (72.5%) | 26 (74.3%) | 3 (60%) |
 Overweight/obese | 0 (0%) | 0 (0%) | 0 (0%) |
Primary site of cancer, n (%) | |||
 Colorectal | 18 (45%) | 17 (48.6%) | 1 (20%) |
 Genitourinary | 6 (15%) | 3 (8.6%) | 3 (60%) |
 Pancreas | 3 (7.5%) | 2 (5.7%) | 1 (20%) |
 Lung | 2 (5%) | 2 (5.7%) | 0 (0%) |
 Upper gastrointestinal tract | 2 (5%) | 2 (5.7%) | 0 (0%) |
 Leukemia and lymphoma | 2 (5%) | 2 (5.7%) | 0 (0%) |
 Others | 7 (17.5%) | 7 (20%) | 0 (0%) |
Stage at diagnosis, n (%) | |||
 Localized | 23 (57.5) | 21 (60%) | 2 (40%) |
 Advanced/metastasis | 17 (42.5) | 14 (40%) | 3 (60%) |
Chemotherapy regimen | |||
 de Gramont/FOLFOX/FOLFIRI | 10 (25%) | 9 (25.7%) | 1 (20%) |
 Paclitaxel + Cisplatin/Carboplatin | 7 (17.5%) | 6 (17.1%) | 1 (20%) |
 FOLFOX + Bevacizumab | 4 (10%) | 4 (11.4%) | 0 (0%) |
 FOLFIRI + Cetuximab | 3 (7.5%) | 3 (8.6%) | 0 (0%) |
 de Gramont + Bevacizumab | 1 (2.5%) | 1 (2.8%) | 0 (0%) |
 Doxorubicin-Ifosfamide | 2 (5%) | 2 (5.7%) | 0 (0%) |
 Cisplatin-Fluorouracil | 2 (5%) | 2 (5.7%) | 0 (0%) |
 Cisplatin+XRT | 3 (7.5%) | 3 (8.6%) | 2 (40%) |
 Gemcitabine + Cisplatin/Carboplatin | 3 (7.5%) | 3 (8.6%) | 0 (0%) |
 UK-ALL protocol | 1 (2.5%) | 1 (2.8%) | 0 (0%) |
 Gemcitabine | 1 (2.5%) | 0 (0%) | 1 (20%) |
 Paclitaxel | 1 (2.5%) | 1 (2.8%) | 0 (0%) |
 R-CHOP | 1 (2.5%) | 1 (2.8%) | 0 (0%) |
 3 + 7 protocol | 1 (2.5%) | 1 (2.8%) | 0 (0%) |
Radiotherapy | 7 (17.5%) | 5 (14.3%) | 2 (40%) |
Laboratory parameters | |||
 Hemoglobin (g/dL) | 11.1 (5.9–16.3) | 10.9 (5.9–16.3) | 11.2 (10.0–12.5) |
 Leukocytes (× 103/μL) | 9.2 (3.9–99.1) | 8.8 (3.88–99.1) | 11.9 (6.3–50.3) |
 Platelets (×103/μL) | 340.0 (51.0–766.0) | 330.2 (51.0–766.0) | 449.5 (200–561) |
 D-dimer (ng/mL) | 1.859.8 (230–11,450) | 1370.12 (230–11,450) | 3920 (460–7140) |
Khorana risk score | |||
 Low risk | 0 (0%) | 0 (0%) | 0 (0%) |
 Intermediate risk | 23 (57.5) | 20 (57.2%) | 3 (60%) |
 Very high risk | 17 (42.5) | 15 (42.8%) | 2 (40%) |